Brücke zwischen Forschern und Patienten

2006-003682-14, Publikation, 01.10.2006 – 01.10.2013, Prof. Dr. med. Jochen Casper, Randomisierte Phase II-Studie zum Einsatz von Pegfilgrastim nach autologer Blutstammzelltransplantation

2007-001262-32, Publikation, 01.06.2007 – 01.02.2013, Prof. Dr. med. Ulrich Gatzemeier, Randomized double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non- small cell lung cancer (NSCLC)

76 2006-003683-54, Auswertung, 01.10.2007 – 31.12.2013, PD Dr. med. Herbert G. Sayer, Palifermin, Prospektive, offene, randomisierte, multizentrische Studie zur Effektivität von Palifermin in der Prophylaxe der Mukositis nach allogener Stammzelltransplantation mit myeloablativer Ganzkörperbestrahlung

Rekrutierung, Prof. Dr. med. Ulrich Germing

2007-003945-33, Rekrutierung, 01.09.2008 – 30.06.2014, PD Dr. med. Guido Kobbe, Lenalidomide (Revlimid®), A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma

2008-001405-41, Publikation, 01.01.2009 – 31.12.2013, Dr. med. Stefan Schönland, Lenalidomide (Revlimid®), A prospective single center trial of treatment with Lenalidomide-Melphalan-Dexamethasone in patients with AL amyloidosis

2009-014677-41, Auswertung, 30.06.2009 – 30.06.2014, Prof. Dr. med. Wolfgang Schütte, Panitumumab, An open-label, randomised, multicentre, phase II clinical study of panitumumab plus pemetrexed and cisplatin (Pem-CisP) versus PemCis in the first-line treatment of patients with stage IIIB or IV primary nonsquamous non-small cell lung cancer, with particular regard to the KRAS status

XIII 2008-004083-39, Rekrutierung, 01.07.2009 – 31.12.2020, Priv.-Doz. Dr. med. Christian Straka, Lenalidomide (Revlimid®), The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myeloma

MM_LEN_DEX_CY 2008-003829-16, Follow-Up, 01.07.2009 – 30.06.2014, PD Dr. med. Martin Kropff, MD, Lenalidomide (Revlimid®), Dexamethasone, Cyclophosphamide, An open, randomized clinical phase I/II trial to investigate maximum tolerated dose, efficacy, and safety of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide compared to lenalidomide/low-dose dexamethasone combined with single cyclophosphamidedoses IV in patients with relapsed/refractory multiple myeloma

2008-001866-10, Behandlung, 01.09.2009 – 30.06.2016, Prof. Dr. med. Ulrich Germing, Lenalidomide (Revlimid®), A multicenter, single-arm, open-label phase II study of the safety of lenalidomide monotherapy and markers for disease progression in patients with IPSS low- or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality (del 5q)

2009-015119-42, Abgeschlossen, 01.09.2009 – 01.10.2013, Prof. Dr. med. Kurt Miller, Panitumumab (GemCisP), An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS

2009-016782-28, Rekrutierung, 01.12.2009 – 31.12.2015, Prof. Dr. med. Ralf-Dieter Hofheinz, Panitumumab (Vectibix®), Panitumumab in combination with radiotherapy in patients with locally advanced KRAS and BRAF wildtype rectal cancer

2009-018025-73, Follow-Up, 01.01.2010 – 31.03.2015, Dr. med. Friedrich Overkamp, Paclitaxel, Randomisierte Phase II Studie zum Vergleich der Paclitaxel Monotherapie vs. Paclitaxel plus Sorafenib in der Zweit- oder Drittlinienbehandlung von Patientinnen mit metastasiertem Brustkrebs (PASO)

2010-018849-59, Rekrutierung, 01.04.2010 – 31.12.2016, Prof. Dr. med. Jalid Sehouli, Panitumumab (Vectibix®), An randomized phase II trial of standard carboplatin and pegylated liposomal doxorubicin with or without panitumumab in platinum-sensitive recurrent ovarian cancer

2010-018339-16, Follow-Up, 01.08.2010 – 31.03.2014, Prof. Dr. med. Andreas Hochhaus, Imatinib (Glivec®), A prospective, multicenter, phase IV study to assess the compliance in patients with Philadelphia chromosome-positive (Ph+) and/or BCR-ABL-positive chronic myelogenous leukemia (CML) under long-term imatinib therapy (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation)

2009-010824-25, Rekrutierung, 01.08.2010 – 31.12.2015, Prof. Dr. med. Bertram Glaß, Lenalidomide (Revlimid®), Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) with Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum

2010-019564-37, Abgeschlossen, 01.12.2010 – 31.12.2013, Prof. Dr. med. Hanno Riess, Doxycycline, Panitumumab, A double blind placebo controlled multicenter Phase II Trial of Skin Toxicity Treatment in Subjects with advanced or metastatic colorectal carcinoma receiving Panitumumab

Vorbereitung, 31.12.2012 – 30.11.2017, Prof. Dr. med. Uwe Platzbecker, National recommendations for the risk-adapted treatment of acute promyelocytic leukemia (APL) APL-Registry 2013

2012-003436-22, Rekrutierung, 01.03.2013 – 31.12.2018, Prof. Dr. med. Ulrich Germing, Romiplosti, 5-Azacitidine, A Phase I Study of Romidepsin Additional to 5-Azacitidine in Higher-risk MDS after Insufficient Response to 5-Azacitidine Monotherapy

2013-004328-12, Vorbereitung, 30.11.2013 – 31.12.2018, Prof. Dr. med. Uwe Platzbecker, Romiplostim, Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia – the EUROPEtrial by the GFM and GMDSSG

2013-002564-69, Vorbereitung, 01.12.2013 – 31.12.2015, Prof. Dr. med. Jalid Sehouli, Romiplostim, Double-blind, placebo-controlled multicenter phase II trial to evaluate the efficacy and safety of romiplostim for the treatment of chemotherapy-induced thrombocytopenia in subjects with relapsed ovarian cancer (2nd and 3rd line)